BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms - Top-Institutions - MDSpire

BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms

  • By

  • Chunyan Wu

  • Yiting Wang

  • Quanchao Zhang

  • Chan Li

  • Yuanzhong Chen

  • Yong Wu

  • June 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Institute of Hematology, Chinese Academy of Medical Sciences
    Institute of Hematology, Chinese Academy of Medical Sciences

    Beijing, Beijing

    Key Differentiators

    • Hematology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Amsterdam University Medical Centers
    Amsterdam University Medical Centers

    Amsterdam, North Holland

    Key Differentiators

    • Hematology

  • #4

    MacKay Memorial Hospital
    MacKay Memorial Hospital

    Taipei, Taiwan

    Key Differentiators

    • Hematology

  • #5

    Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms

  • by Chunyan Wu, Yiting Wang, Quanchao Zhang, Chan Li, Yuanzhong Chen, Yong Wu

  • June 2, 2026

Related Content

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

This Week’s CGT News: Base Editing Takes Aim at Cholesterol

Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M

  • June 1, 2026

  • 5 min
HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee